Active Ingredient(s): Denileukin Deftitox
FDA Approved: * February 5, 1999
Pharm Company: * SERAGEN
Category: Cancer

Denileukin diftitox (trade name Ontak) was an antineoplastic agent, an engineered protein combining interleukin-2 and diphtheria toxin. Denileukin diftitox could bind to interleukin-2 receptors[1] and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some leukemias and lymphomas, malignant cells express these receptors, so denileukin diftitox can target these. In 1999, Ontak was approved by the U.S. Food and Drug Administration (F... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Ontak 150 ug/ml Intravenous Injection, Solution
NDC: 62856-603
Eisai Inc.